Bromodomain-containing protein 1 (BRD1) (BRD1)

Bromodomain-containing protein 1 (BRD1), also known as BRPF2, is a scaffold protein that plays a pivotal role in the regulation of chromatin structure and gene expression (UniProt: P55201) [1]. It is a member of the BRPF (Bromodomain and PHD Finger) family and serves as a critical component of histone acetyltransferase (HAT) complexes, such as the HBO1 (KAT7) and MOZ/MORF complexes (PMID: 24362250) [5]. By utilizing its bromodomain to recognize and bind acetylated lysine residues on histone tails, BRD1 directs HAT activity to specific genomic regions, facilitating transcriptional activation. Biologically, BRD1 is essential for erythropoiesis and proper brain development, with its dysfunction linked to neurodevelopmental disorders (PMID: 24362250) [5]. Genetic studies have identified BRD1 as a susceptibility gene for schizophrenia and bipolar disorder, suggesting its importance in maintaining mental health (PMID: 17310231) [3]. In the context of oncology, BRD1 is involved in the maintenance of certain leukemic states and the progression of various cancers. Small molecule inhibitors, such as GSK6853, have been developed to target the BRD1 bromodomain, offering a potential therapeutic strategy for treating psychiatric and malignant diseases (PMID: 28240517) [2]. These inhibitors work by competitively blocking the interaction between the bromodomain and acetylated histones, thereby modulating the epigenetic landscape of the cell (PMID: 27501354) [4].

Other names

BRPF2Bromodomain and PHD finger-containing protein 2BR1

Competitive inhibition of the bromodomain-acetyl-lysine interaction, which prevents the recruitment of histone acetyltransferase complexes to chromatin, thereby reducing site-specific histone acetylation and modulating gene transcription (PMID: 28240517) [2].